| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALLO | Common Stock | Award | $0 | +19.1K | +3.6% | $0.00 | 550K | Oct 7, 2022 | Direct | F1 |
| transaction | ALLO | Common Stock | Tax liability | -$100K | -8.46K | -1.54% | $11.83 | 542K | Oct 7, 2022 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | Represents the vesting of performance-based restricted stock units (Performance RSUs) granted on September 3, 2019. Performance RSUs vested upon the initiation of a Phase 2 clinical trial of ALLO-501A. Each Performance RSU represents the right to receive one share of common stock of the Issuer. |
| F2 | Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.7081 to $11.845, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |